SOBRsafe Inc. (NASDAQ: SOBR), a provider of next-generation alcohol detection technology, has entered into definitive agreements for the immediate exercise of certain outstanding warrants at a reduced exercise price of $1.05 per share, generating expected gross proceeds of approximately $3.1 million before fees and expenses. The transaction, announced in a press release, involves the issuance of new unregistered Series E and Series F warrants to purchase an aggregate of 4.7 million shares. The offering is expected to close on or about July 16, 2026, with net proceeds designated for working capital and general corporate purposes. H.C. Wainwright & Co. is serving as the exclusive placement agent.
The capital raise is a strategic move for SOBRsafe as it continues to advance its transdermal alcohol detection technology, which detects and reports in real-time the presence of alcohol as emitted through a user's skin, without requiring breath, blood, or urine samples. The company's technology is designed for passive, dignified screening and monitoring solutions across behavioral health, family law, consumer markets, and licensing and integration. With a powerful backend data platform, SOBRsafe aims to enable trust and empower recovery with a human touch.
The warrant exercise agreements allow SOBRsafe to secure immediate funding while minimizing dilution to existing shareholders compared to a traditional equity offering. The reduced exercise price incentivizes warrant holders to convert, providing the company with much-needed capital to support its operations and growth initiatives. The net proceeds will be used for working capital and general corporate purposes, which may include research and development, sales and marketing, and potential strategic partnerships.
This news is important as it demonstrates SOBRsafe's ability to access capital markets and strengthen its balance sheet. The company's innovative alcohol detection technology addresses a critical need in markets such as behavioral health and family law, where accurate and non-invasive monitoring is essential. By securing additional funding, SOBRsafe is better positioned to scale its operations and expand its market presence.
Investors and stakeholders can find the latest news and updates relating to SOBR in the company's newsroom at https://nnw.fm/SOBR. For more details on the warrant exercise agreements, the full press release is available at https://nnw.fm/jzJjF.
SOBRsafe's transdermal technology represents a significant advancement in alcohol detection, offering a passive and dignified alternative to traditional methods. As the company continues to commercialize its solutions, this capital infusion will support its mission to enable trust and empower recovery.
